Imbruvica (Tablet)

IBRUTINIB Pharmacyclics
140,560 mg; Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
Used to treat certain cancers (such as mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia)
Yes
***** ** ***. ***** ***** * **** ** *** *** *********. ** ****** **** **** ***** ****** ** **** ****. *****, ***** ****** *** ****** **** ***** * **** ** *** **** *********. ******** ****** ** ********* ****** ** *** ****. **, **** ** *** ******** *** ****** ******* ****** *** ****. ***** ************* *** ***** **** ******* **** *********** *****. ****, ***** (*******) **** *** **** ******* ****** ****** ** ******* '***, '***, '***, '***. **, ***** ***'* ****** *** ******* ****** *** ****. ***** (*******) ******** ** ******* ***** ** *** **, ****.
Imbruvica (Tablet) Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16 Patent 17 Patent 18 Patent 19 Patent 20 Patent 21 Patent 22 Patent 23 Patent 24 Patent 25 Patent 26 Patent 27 Patent 28 Patent 29 Patent 30 Patent 31 Patent 32 Patent 33 Patent 34
*****(*******) **** ** ** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ** **** ** ***** *,**** **** ** ** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* **** ** ***** *,**** *** ********* **** ** ***** *,**** *** ********* **** ** **** **, **** **** ** ***** *,**** **** ** ** *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** *********
***** ****** ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *** ********* *** ********* *** ********* *** ********* ******* *** ********* **** ** ***** **, **** *** ********* ******* **** ** ***** **, **** *** ********* *** ********* **** ** *** **, **** ******* ******* ******* ******* *******
****** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*****(*******) *** \ ********* **** *, **** **** ** ** / ******* ********* ******** ***** *** ****
** ******* ** \ ** *** **, **** ******* **** ***** *** **** (***** ******)
****** ** \ ** *** **, **** ******* **** ***** *** **** (***** ******)
  1. *** **, **** : ***** ****** ************* **** **** ** ****** **** *** **** ** *************.
  2. *** *, **** : ***** ****** ************* **** **** ** ****** **** *** **** ** ************* ** *** ** *** *** ** ******.
  3. *** **, **** : ***** ****** ************* **** **** ** ****** **** *** **** ** ************* ** *** ** *** *** ** *****.
  4. *** *, **** : ************* ***** * **** ******* *****(*******) ** ******* '***, '***, '***, '***, '***, '***, '***, '***, '***, '*** (*** **, ****), '*** (**** *, ****), '*** (*** **, ****), '***, '***, '*** (**** *, ****), '***, '*** (***** *,****)
  5. *** **, **** : ************* ***** * **** ******* *****(*******) ** ****** '*** (***** *,****) *** ** ******* ********* ** ******* '***, '***, '***, '***, '***, '***, '***, '***, '***, '*** (*** **, ****), '*** (**** *, ****), '*** (*** **, ****), '***, '***, '*** (**** *, ****), '***, '*** (***** *,****)
  6. *** **, **** : ***** ****** ******** ************ ***** **'* **** ** ****** ** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, *** ’***
  7. *** **, **** : ************* ***** * **** ******* *****(*******) ** ******* '***, '***, '***, '*** *** '***
  8. *** **, **** : ************ ***** * **** ******* ***** ****** ** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, *** ’***
  9. *** **, **** : ************ ***** * **** ******* ***** ****** *** ****** ** ******* '***, '***, '***, '*** *** '***
  10. *** **, **** : ************ ***** * **** ******* ***** ****** ** ****** '***
  11. *** **, **** : **** ******* ******* ************* *** ***** ******.
  12. *** **, **** : ***** (*******) **** ** ******** ***** **** ******* '*** (*** **,****), '*** (**** *, ****), '*** (**** *, ****) *** '*** (***** *, ****).
  13. *** **, **** : ***** (*******) ******** ** ******* *****.

Imbruvica (Tablet)

IBRUTINIB Pharmacyclics
280,420 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with: Mantle cell lymphoma (MCL) who have received at least one prior treatment. Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion.
Yes
***** ** ***. ***** ***** * **** ** *** *** *********. ** ****** **** **** ***** ****** ** **** ****. *****, ***** ****** *** ****** **** ***** * **** ** *** **** *********. ******** ****** ** ********* ****** ** *** ****. **, **** ** *** ******** *** ****** ******* ****** *** ****. ***** ************* *** ***** **** ******* **** *********** *****. ****, ***** (*******) **** *** **** ******* ****** ****** ** ******* '***, '***, '***, '***. **, ***** ***'* ****** *** ******* ****** *** ****. ***** (*******) ******** ** ******* ***** ** *** **, ****.
Imbruvica (Tablet) Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16 Patent 17 Patent 18 Patent 19 Patent 20 Patent 21 Patent 22 Patent 23 Patent 24 Patent 25 Patent 26 Patent 27 Patent 28 Patent 29 Patent 30 Patent 31 Patent 32 Patent 33 Patent 34
*****(*******) **** ** ** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ***** *,**** **** ** ** **** ** ***** *,**** **** ** ** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* **** ** ***** *,**** *** ********* **** ** ***** *,**** *** ********* **** ** **** **, **** **** ** ***** *,**** **** ** ** *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** *********
***** ****** ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *** ********* *** ********* *** ********* *** ********* ******* *** ********* **** ** ***** **, **** *** ********* ******* **** ** ***** **, **** *** ********* *** ********* **** ** *** **, **** ******* ******* ******* ******* *******
****** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*****(*******) *** \ ********* **** *, **** **** ** ** / ******* ********* ******** ***** *** ****
***** ****** ** \ ** *** **, **** ******* **** ***** *** **** (***** ******)
****** ** \ ** *** **, **** ******* **** ***** *** **** (***** ******)
  1. *** **, **** : ***** ****** ************* **** **** ** ****** **** *** **** ** ************* ** *** ** *** *** ** *****.
  2. *** *, **** : ************* ***** * **** ******* *****(*******) ** ******* '***, '***, '***, '***, '***, '***, '***, '***, '***, '*** (*** **, ****), '*** (**** *, ****), '*** (*** **, ****), '***, '***, '*** (**** *, ****), '***, '*** (***** *,****)
  3. *** **, **** : ************* ***** * **** ******* *****(*******) ** ****** '*** (***** *,****) *** ** ******* ********* ** ******* '***, '***, '***, '***, '***, '***, '***, '***, '***, '*** (*** **, ****), '*** (**** *, ****), '*** (*** **, ****), '***, '***, '*** (**** *, ****), '***, '*** (***** *,****)
  4. *** **, **** : ***** ****** ******** ************ ***** **'* **** ** ****** ** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, *** ’***
  5. *** **, **** : ************* ***** * **** ******* *****(*******) ** ******* '***, '***, '***, '*** *** '***
  6. *** **, **** : ************ ***** * **** ******* ***** ****** ** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, *** ’***
  7. *** **, **** : ************ ***** * **** ******* ***** ****** *** ****** ** ******* '***, '***, '***, '*** *** '***
  8. *** **, **** : ************ ***** * **** ******* ***** ****** ** ****** '***
  9. *** **, **** : **** ******* ******* ************* *** ***** ******.
  10. *** **, **** : ***** (*******) **** ** ** **** ******* '*** (*** **, ****), ' *** (**** *, ****), '*** (**** *, ****) *** '*** (***** *, ****).
  11. *** **, **** : ***** (*******) ******** ** ******* *****.
  Download as PDF

Advance Search






Please contact nimish@researchdelta.com to get more details.

Para IV Insights – Our Premium Offerings

Key Developments

This is a monthly report highlighting the important developments in the Para IV space. This will not contain any analysis.

View Sample

Para IV Winners and Losers

This is a monthly report that captures all the important developments in the Para IV space along with the analyses of timing of generic launch and likely competition.

View Sample


Para IV Database

This is the entire database that offers the information and analyses of each product currently under Para IV litigation. Subscribers will also get options to search Para IV information by companies as well as with product (Generic or Brand).

View Sample

NCE Exclusivity Data till 2024

We offer you the list of all those Orange Book products where NCE Exclusivity will expire between 2019 through 2024.

View Sample